188 related articles for article (PubMed ID: 33054725)
1. Clinical characteristics and prognostic implications of BRCA-associated tumors in males: a pan-tumor survey.
Sun P; Li Y; Chao X; Li J; Luo R; Li M; He J
BMC Cancer; 2020 Oct; 20(1):994. PubMed ID: 33054725
[TBL] [Abstract][Full Text] [Related]
2. BRCA testing and outcomes in women with breast cancer.
Stenehjem DD; Telford C; Unni SK; Bauer H; Sainski A; Deka R; Schauerhamer MB; Ye X; Tak CR; Ma J; Dalvi TB; Gutierrez L; Kaye JA; Tyczynski JE; Brixner DI; Biskupiak JE
Breast Cancer Res Treat; 2021 Apr; 186(3):839-850. PubMed ID: 33389410
[TBL] [Abstract][Full Text] [Related]
3. Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
Ibrahim M; Yadav S; Ogunleye F; Zakalik D
BMC Cancer; 2018 Feb; 18(1):179. PubMed ID: 29433453
[TBL] [Abstract][Full Text] [Related]
4. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.
Golan T; Sella T; O'Reilly EM; Katz MH; Epelbaum R; Kelsen DP; Borgida A; Maynard H; Kindler H; Friedmen E; Javle M; Gallinger S
Br J Cancer; 2017 Mar; 116(6):697-702. PubMed ID: 28183138
[TBL] [Abstract][Full Text] [Related]
5. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study.
Golan T; Raitses-Gurevich M; Kelley RK; Bocobo AG; Borgida A; Shroff RT; Holter S; Gallinger S; Ahn DH; Aderka D; Apurva J; Bekaii-Saab T; Friedman E; Javle M
Oncologist; 2017 Jul; 22(7):804-810. PubMed ID: 28487467
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of female breast cancer according to BRCA mutation status.
Cronin-Fenton DP; Kjærsgaard A; Nørgaard M; Pedersen IS; Thomassen M; Kaye JA; Gutierrez L; Telford C; Lewis J; Tyczynski JE; Sørensen HT
Cancer Epidemiol; 2017 Aug; 49():128-137. PubMed ID: 28601786
[TBL] [Abstract][Full Text] [Related]
7. Assessing frequency and clinical outcomes of BRCA mutated ovarian cancer in Saudi women.
Agha N; Alshamsan B; Al-Farsi S; Ateya HA; Almugbel FA; Alotaibi HA; Omar A; Mohamed AS; Alharthy H; Elhassan T; Salem H; Alhusaini H
BMC Cancer; 2022 Jan; 22(1):18. PubMed ID: 34980015
[TBL] [Abstract][Full Text] [Related]
8. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
9. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
10. BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study.
Unni SK; Schauerhamer MB; Deka R; Tyczynski JE; Fernandes AW; Stevens V; Brixner DI; Stenehjem DD
J Ovarian Res; 2016 Mar; 9():18. PubMed ID: 27004793
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
Sønderstrup IMH; Jensen MB; Ejlertsen B; Eriksen JO; Gerdes AM; Kruse TA; Larsen MJ; Thomassen M; Laenkholm AV
Acta Oncol; 2019 Mar; 58(3):363-370. PubMed ID: 30614364
[TBL] [Abstract][Full Text] [Related]
12. PARP Inhibitor Insensitivity to
Sokol ES; Jin DX; Fine A; Trabucco SE; Maund S; Frampton G; Molinero L; Antonarakis ES
JCO Precis Oncol; 2022 Jun; 6():e2100531. PubMed ID: 35772050
[TBL] [Abstract][Full Text] [Related]
13. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
[TBL] [Abstract][Full Text] [Related]
14. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
Oh M; Alkhushaym N; Fallatah S; Althagafi A; Aljadeed R; Alsowaida Y; Jeter J; Martin JR; Babiker HM; McBride A; Abraham I
Prostate; 2019 Jun; 79(8):880-895. PubMed ID: 30900310
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis.
Xu K; Yang S; Zhao Y
Oncotarget; 2017 Jan; 8(1):285-302. PubMed ID: 27690218
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer.
Colombo N; Huang G; Scambia G; Chalas E; Pignata S; Fiorica J; Van Le L; Ghamande S; González-Santiago S; Bover I; Graña Suárez B; Green A; Huot-Marchand P; Bourhis Y; Karve S; Blakeley C
J Clin Oncol; 2018 May; 36(13):1300-1307. PubMed ID: 29558274
[TBL] [Abstract][Full Text] [Related]
17. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
[TBL] [Abstract][Full Text] [Related]
18. Oncologist-led BRCA 'mainstreaming' in the ovarian cancer clinic: A study of 255 patients and its impact on their management.
Rumford M; Lythgoe M; McNeish I; Gabra H; Tookman L; Rahman N; George A; Krell J
Sci Rep; 2020 Feb; 10(1):3390. PubMed ID: 32098980
[TBL] [Abstract][Full Text] [Related]
19. Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis.
Sabatier R; Lavit E; Moretta J; Lambaudie E; Noguchi T; Eisinger F; Cherau E; Provansal M; Livon D; Rabayrol L; Popovici C; Charaffe-Jauffret E; Sobol H; Viens P
Fam Cancer; 2016 Oct; 15(4):497-506. PubMed ID: 26833043
[TBL] [Abstract][Full Text] [Related]
20. CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.
Plevova P; Cerna D; Balcar A; Foretova L; Zapletalova J; Silhanova E; Curik R; Dvorackova J
Neoplasma; 2010; 57(4):325-32. PubMed ID: 20429623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
